c/survodutide · created 14 Feb 2024
GLP-1/glucagon dual agonist. MASH data and the hepatic angle.
The phase 2 MASH results ( NEJM , 2024) are, to me, the most underdiscussed thing in this whole space. Biopsy-confirmed endpoints. Not an ALT screenshot, not imaging,…
survodutide MASH data is the most interesting hepatic readout in the class. Change my mind, genuinely — I have no stake in being right about this. Nothing containing…
Thinking out loud about this: phase 2 biopsy endpoints, and what "resolution" means. The honest evidence position, written out so this board does not drift. Phase 2…
Trying to get a straight answer on this: does the glucagon arm explain the heart rate signal. The escalation schedules in the published protocols are slow and…
Reference standards, analytical reagents and system-suitability material. If you are running your own method, start with a known.
Reference standardssmall community, high signal, let us keep it that way. Change my mind, genuinely — I have no stake in being right about this. Nothing containing this compound is…
Something I keep coming back to: hepatic endpoints need biopsy data, not an ALT screenshot. Sent a vial to Janoshik because there was nothing on file. 98.4% against a…
Housekeeping: proposal — a flair for dual agonist posts. Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human…
The title is the whole question — am I the only one who found hepatic fat harder than the injections — but here is why I am asking. Independent purity results for this…
is it normal to get constipation at week 7, logged the same way every week so the comparison is at least internally fair. Assumed the weight numbers were the point and…
The title is the whole question — does MASH actually matter or is it forum lore at this point — but here is why I am asking. Independent purity results for this…
GGPeps survo — VendorInvestigate came back 97.9% against a claimed 97.0%, and before anyone asks: same batch throughout, single submission, no cherry-picking between…
three years of glucagon threads, summarised so you do not have to read them, which sounds obvious until you try to state the evidence for it. It is a dual agonist at…
Short public-service post: dual agonist is not what most of this community thinks it is. Asked here what the difference was between the imaging and biopsy endpoints and…
The title is the whole question — glucagon — what am I missing here — but here is why I am asking. It is a dual agonist at the GLP-1 and glucagon receptors. The…
Six-word version is the title — anyone else notice survodutide kicking in around week 93 — and the rest is context. Read the phase 2 hepatic paper properly and the…
Send the vial, get the number. Third-party purity and identity testing, results published to you regardless of what they say.
Test a vialSponsoredEst. 1998. ISO 9001 and cGMP, 1,500+ staff, 200+ patents. There is a fair chance the vial you are about to send for testing started here. Batch-specific COA as standard.
glbiochem.net28 weeks, 11kg, and MASH was the hard part. Same spreadsheet I have been keeping since the start, nothing retrofitted. Since the title puts numbers in the shop window:…
why does nobody talk about dual agonist, and I want the answer with the reasoning attached rather than just the conclusion. Assumed the weight numbers were the point…
Result first, context after: BCH vs KP on the same compound, same month — both cleared 98.5% . Everything below is how it was ordered, stored and sent. Figures up front…
hepatic fat is doing more work than we give it credit for. Making the case below, and I expect to lose some of it in the comments. Imaging-derived liver fat fraction is…
biopsy is the most under-discussed thing on this board. I have gone back and forth on this for months. Phase 2 in a biopsy-confirmed population is a demanding design:…
the MASH thing finally clicked for me and I want to write it down, which sounds obvious until you try to state the evidence for it. Independent purity results for this…
how do you actually verify MASH. I would rather ask a basic question now than get this wrong quietly for two months. Read the phase 2 hepatic paper properly and the…
stalled for 8 weeks at 1.7mg and I refuse to panic this time. Making the case below, and I expect to lose some of it in the comments. Since the title puts numbers in…
three years of survodutide threads, summarised so you do not have to read them. Not a hot take, just something I have not seen said plainly here. Histological endpoints…
MASH — my 24-week log, condensed into one table, which sounds obvious until you try to state the evidence for it. It is a dual agonist at the GLP-1 and glucagon…
Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference